TABLE 4.
Haplotypic associations between CDHR3 SNPs and clinical outcomes from RV infections
| Diagnosis | Combination of CDHR3 SNPs | Haplotype | Frequency | OR (95% CI) | P value a |
|---|---|---|---|---|---|
| RV-C infection | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.182 | 1.06 (0.84–1.34) | 0.625 | ||
| AC | 0.050 | 1.07 (0.71–1.61) | 0.757 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 1.10 (0.89–1.35) | 0.395 | ||
| GAA | 0.050 | 1.28 (0.84–1.94) | 0.257 | ||
| GAG | 0.046 | 1.71 (1.11–2.65) b | 0.016 | ||
| Lower RTI | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.183 | 0.88 (0.70–1.11) | 0.289 | ||
| AC | 0.050 | 1.55 (1.02–2.37) | 0.041 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 0.96 (0.78–1.18) | 0.685 | ||
| GAA | 0.050 | 1.15 (0.76–1.76) | 0.512 | ||
| GAG | 0.046 | 1.14 (0.75–1.73) | 0.554 | ||
| RV-C-associated lower RTI | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.182 | 0.97 (0.75–1.25) | 0.822 | ||
| AC | 0.050 | 1.53 (1.00–2.35) | 0.052 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 1.04 (0.83–1.31) | 0.734 | ||
| GAA | 0.050 | 1.25 (0.80–1.95) | 0.329 | ||
| GAG | 0.046 | 1.42 (0.92–2.20) | 0.111 | ||
| Wheeze | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.183 | 0.88 (0.70–1.11) | 0.386 | ||
| AC | 0.050 | 1.49 (0.98–2.27) | 0.062 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.373 | 0.99 (0.80–1.23) | 0.945 | ||
| GAA | 0.050 | 1.23 (0.81–1.88) | 0.335 | ||
| GAG | 0.046 | 1.14 (0.75–1.73) | 0.544 | ||
| RV-C-associated wheeze | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.183 | 0.94 (0.73–1.21) | 0.633 | ||
| AC | 0.050 | 1.39 (0.90–2.14) | 0.142 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 1.03 (0.82–1.29) | 0.821 | ||
| GAA | 0.050 | 1.26 (0.81–1.98) | 0.308 | ||
| GAG | 0.046 | 1.37 (0.89–2.13) | 0.158 | ||
| Asthma exacerbation | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.182 | 0.93 (0.71–1.23) | 0.632 | ||
| AC | 0.050 | 1.10 (0.68–1.79) | 0.687 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 0.79 (0.61–1.03) | 0.078 | ||
| GAA | 0.050 | 0.93 (0.57–1.52) | 0.774 | ||
| GAG | 0.046 | 1.02 (0.62–1.67) | 0.954 | ||
| RV-C-associated asthma exacerbation | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.182 | 1.06 (0.78–1.43) | 0.715 | ||
| AC | 0.050 | 0.93 (0.53–1.64) | 0.808 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 0.86 (0.64–1.14) | 0.289 | ||
| GAA | 0.050 | 1.15 (0.68–1.95) | 0.610 | ||
| GAG | 0.046 | 1.21 (0.72–2.06) | 0.470 | ||
| Oxygen supplement | rs3887998_rs73195657 | GT | 0.765 | Reference | |
| AT | 0.183 | 0.68 (0.45–1.01) | 0.057 | ||
| AC | 0.049 | 1.25 (0.68–2.29) | 0.474 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.371 | 0.97 (0.69–1.37) | 0.876 | ||
| GAA | 0.051 | 0.85 (0.42–1.73) | 0.655 | ||
| GAG | 0.046 | 1.93 (1.13–3.30) | 0.016 | ||
| Systemic corticosteroid | rs3887998_rs73195657 | GT | 0.764 | Reference | |
| AT | 0.183 | 0.83 (0.60–1.16) | 0.286 | ||
| AC | 0.050 | 1.50 (0.89–2.51) | 0.128 | ||
| rs4730125_rs6967330_rs73195665 | GGG | 0.530 | Reference | ||
| TGG | 0.372 | 0.87 (0.64–1.18) | 0.373 | ||
| GAA | 0.050 | 1.53 (0.91–2.57) | 0.108 | ||
| GAG | 0.046 | 1.25 (0.73–2.16) | 0.420 |
a
Adjusted for age and sex as covariates.
b
Statistically significant results are highlighted in bold.